Foghorn Therapeutics Inc (FHTX) Stock Price, Quote & News

Company Profile

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-ce...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 586 3100

Website: foghorntx.com

Address:

99 Coolidge Avenue, Suite 500, Watertown, United States

AnomalyDetective Aug. 15 at 4:45 PM

💥Long term portfolio returns YTD through Week 33. S&P 500 #SPX up +14.3% including dividends. 💥All new weekly MDA breakout stocks for members up +167.3% in average cumulative returns with Week 34 selections here : 👉 https://seekingalpha.com/mp/1201-value-momentum-breakouts/articles/6328699-august-mda-breakout-stocks-week-34-and-highlighted-top-gainers 💥 Last week MDA breakout picks had peak gains +15.94% led by $TIC $FHTX

0 · Reply

Zephix Aug. 13 at 11:08 PM

$FHTX Hog2

0 · Reply

AnomalyDetective Aug. 13 at 12:56 PM

💥 New Week 34 MDA breakout picks released today in advance for members after the close while S&P 500 $SPY intraday road map continues in Segment 4 chop with Sector Gauges divided. 💥 Week 33 MDA picks with 3 out of 4 selections beating 10% gains in less than a week led by $FHTX $TIC with peak gains so far over +21%. 💥 MDA breakouts average cumulative return +168.3% YTD extending the count to 377 weeks with at least one pick gaining over 10% in less than a week... 3 of 4 so far this week.

0 · Reply

vu_jade Aug. 10 at 3:59 PM

$FHTX long term reversal going on

0 · Reply

AnomalyDetective Aug. 10 at 3:26 PM

🌟 $FHTX becomes the 3rd of 4 picks for Week 33 to break 10% for members through Monday. Extending the count to 377 weeks with at least one weekly pick gaining over 10% in less than a week. 🌟 Week 33 MDA picks are up +11.4% through Monday with all picks positive. Increasing the average cumulative weekly breakout returns to +169.4% YTD. 💥 Up to 12,600 daily picks per year available on the automated http://vmbreakouts.com website with prior free samples at http://top.vmbreakouts.com

0 · Reply

cea Aug. 7 at 10:11 PM

$FHTX $GSK $LLY $SLS $VKTX Has nothing to do with any of the other tickers. Stop spamming @Stocktwits reporting. BLOCKED!

0 · Reply

wyoming2020 Aug. 7 at 8:53 PM

$FHTX interesting move today $LLY Partnered lead for cancer

0 · Reply

wyoming2020 Aug. 7 at 8:50 PM

$GSK $FHTX $SLS $LLY $VKTX a big move up at Foghorn for the Mir onco-protein degrader (Lily partnered) maybe something starting to form there. Just placing heads up as Foghorn a sleeper last 6 months or so.

0 · Reply

RandomInvestor777 Jul. 14 at 4:41 PM

$FHTX why is this so dead volume wise

0 · Reply

justiceforb_85 Jul. 13 at 12:25 AM

$FHTX wondering how folks felt about FHD-909/LY4050784 when prelude tried the SMARCA2 target before and showed underwhelming results? Are they mainly focusing on combination strategy with keytruda for esophageal/lung?

1 · Reply

Foghorn Therapeutics reports Q2 EPS (10c), consensus (23c)

Aug 6, 2026, 7:00 AM EDT - 13 days ago

Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update

Aug 6, 2026, 7:00 AM EDT - 13 days ago

Foghorn Therapeutics Quarterly report: Q2 2026

Aug 6, 2026, 7:00 AM EDT - 13 days ago

Foghorn Therapeutics Earnings release: Q2 2026

Aug 6, 2026, 7:00 AM EDT - 13 days ago

Foghorn Therapeutics Slides: Investor presentation

Jul 1, 2026, 7:00 AM EDT - 7 weeks ago

Step Pharma announces the appointment of Neil Gallagher as Non-Executive Director

Jun 9, 2026, 1:30 PM EDT - 2 months ago

Foghorn Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 5, 2026, 7:00 AM EDT - 2 months ago

Foghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026

May 12, 2026, 7:00 AM EDT - 3 months ago

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May

2026-05-07T15:01:40.000Z - 3 months ago

Foghorn Therapeutics reports Q1 EPS (29c), consensus (31c)

May 7, 2026, 7:00 AM EDT - 3 months ago

Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update

May 7, 2026, 7:00 AM EDT - 3 months ago

Foghorn Therapeutics Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 3 months ago

Foghorn Therapeutics Earnings release: Q1 2026

May 6, 2026, 7:00 AM EDT - 3 months ago

Foghorn Therapeutics Slides: Investor presentation

Apr 30, 2026, 8:00 AM EDT - 3 months ago

Foghorn Therapeutics Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 3 months ago

Foghorn Therapeutics Proxy statement: Proxy filing

2026-04-21T21:02:02.000Z - 4 months ago

Foghorn Therapeutics presents new preclinical data for FHD-909

Apr 21, 2026, 4:05 PM EDT - 4 months ago

Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting

Apr 9, 2026, 7:00 AM EDT - 4 months ago

Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting

Mar 11, 2026, 5:00 PM EDT - 5 months ago

Foghorn Therapeutics Annual report: Q4 2025

Mar 11, 2026, 5:00 PM EDT - 5 months ago

Foghorn Therapeutics Earnings release: Q4 2025

Mar 11, 2026, 4:09 PM EDT - 5 months ago

Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook

Mar 9, 2026, 7:00 AM EDT - 5 months ago

Foghorn Therapeutics Slides: Investor presentation

Mar 3, 2026, 11:10 AM EST - 6 months ago

Foghorn Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 7:00 AM EST - 6 months ago

Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences

2026-02-23T12:13:58.000Z - 6 months ago

Foghorn Therapeutics appoints Maynard as Chief Financial Officer

Feb 23, 2026, 7:00 AM EST - 6 months ago

Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer

2026-02-17T11:21:35.000Z - 6 months ago

Foghorn Therapeutics price target lowered to $12 from $14 at Jefferies

Feb 11, 2026, 3:00 PM EST - 6 months ago

Foghorn Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 3, 2026, 7:00 AM EST - 7 months ago

Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit

Jan 13, 2026, 4:05 PM EST - 7 months ago

Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium

Jan 9, 2026, 10:20 PM EST - 7 months ago

Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026

2025-12-18T11:55:21.000Z - 8 months ago

Foghorn Therapeutics initiated with a Buy at BTIG

Dec 4, 2025, 9:10 AM EST - 9 months ago

Foghorn Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

2025-12-03T21:20:41.000Z - 9 months ago

Foghorn Therapeutics initiated with a Buy at Stifel

LLY

Nov 25, 2025, 7:00 AM EST - 9 months ago

Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

Nov 19, 2025, 5:30 AM EST - 9 months ago

Foghorn Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 10, 2025, 11:00 AM EST - 10 months ago

Foghorn Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

2025-11-07T11:30:50.000Z - 10 months ago

Foghorn Therapeutics initiated with a Buy at Guggenheim

Nov 5, 2025, 4:00 PM EST - 10 months ago

Foghorn Therapeutics Earnings release: Q3 2025

Nov 5, 2025, 4:00 PM EST - 10 months ago

Foghorn Therapeutics Quarterly report: Q3 2025

2025-11-05T12:06:26.000Z - 10 months ago

Foghorn Therapeutics reports Q3 EPS (25c), consensus (30c)

Nov 5, 2025, 7:00 AM EST - 10 months ago

Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update

Nov 3, 2025, 7:30 AM EST - 10 months ago

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences

Oct 30, 2025, 12:00 PM EDT - 10 months ago

Foghorn Therapeutics Transcript: 8th Annual Targeted Protein Degradation & Induced Proximity Summit

2025-10-30T11:41:51.000Z - 10 months ago

Foghorn announces updates for Selective ARID1B, Selective CBP, Selective EP300

Oct 30, 2025, 7:30 AM EDT - 10 months ago

Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs

2025-10-16T11:10:48.000Z - 10 months ago

Foghorn Therapeutics announces progress for Selective ARID1B degrader program

Oct 16, 2025, 7:00 AM EDT - 10 months ago

Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit

2025-09-17T12:40:20.000Z - 1 year ago

Foghorn Therapeutics transferred with Buy rating at B. Riley

Aug 28, 2025, 8:00 AM EDT - 1 year ago

IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies

IQV MRNA SANA

2025-08-05T14:45:31.000Z - 1 year ago

Foghorn Therapeutics management to meet virtually with B. Riley

2025-08-05T11:16:10.000Z - 1 year ago

Foghorn Therapeutics reports Q2 EPS (28c), consensus (32c)

Aug 5, 2025, 7:00 AM EDT - 1 year ago

Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update

Aug 5, 2025, 7:00 AM EDT - 1 year ago

Foghorn Therapeutics Earnings release: Q2 2025

Aug 5, 2025, 7:00 AM EDT - 1 year ago

Foghorn Therapeutics Quarterly report: Q2 2025

Jun 5, 2025, 3:45 PM EDT - 1 year ago

Foghorn Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

May 22, 2025, 7:00 AM EDT - 1 year ago

Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences

2025-05-14T11:06:24.000Z - 1 year ago

Foghorn Therapeutics reports Q1 EPS (30c), consensus (29c)

2025-05-14T11:06:16.000Z - 1 year ago

Foghorn Therapeutics sees cash runway into 2027

May 14, 2025, 7:00 AM EDT - 1 year ago

Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update

May 14, 2025, 7:00 AM EDT - 1 year ago

Foghorn Therapeutics Earnings release: Q1 2025

May 14, 2025, 7:00 AM EDT - 1 year ago

Foghorn Therapeutics Quarterly report: Q1 2025

May 5, 2025, 8:00 AM EDT - 1 year ago

Foghorn Therapeutics Proxy statement: Proxy Filing

May 5, 2025, 8:00 AM EDT - 1 year ago

Foghorn Therapeutics Proxy statement: Proxy Filing

May 5, 2025, 7:00 AM EDT - 1 year ago

Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference

2025-05-01T11:41:55.000Z - 1 year ago

Foghorn Therapeutics appoints Neil Gallagher, Stuart Duty to board

May 1, 2025, 7:00 AM EDT - 1 year ago

Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Foghorn Therapeutics Transcript: AACR Annual Meeting 2025

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Foghorn Therapeutics Slides: FY 2025

2025-04-28T20:45:06.000Z - 1 year ago

Foghorn Therapeutics announces new preclinical data at AACR

Apr 28, 2025, 4:05 PM EDT - 1 year ago

Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update

2025-04-23T09:35:31.000Z - 1 year ago

Foghorn Therapeutics initiated with an Outperform at Citizens JMP

Apr 15, 2025, 7:00 AM EDT - 1 year ago

Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting

Mar 25, 2025, 4:35 PM EDT - 1 year ago

Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting

Mar 6, 2025, 4:05 PM EST - 1 year ago

Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook

Mar 6, 2025, 4:00 PM EST - 1 year ago

Foghorn Therapeutics Annual report: Q4 2024

Mar 6, 2025, 4:00 PM EST - 1 year ago

Foghorn Therapeutics Earnings release: Q4 2024

Mar 3, 2025, 2:30 PM EST - 1 year ago

Foghorn Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Jan 24, 2025, 7:00 AM EST - 1 year ago

Foghorn Therapeutics Registration statement: Registration Filing

Dec 16, 2024, 7:00 AM EST - 1 year ago

Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities

Dec 3, 2024, 1:20 PM EST - 1 year ago

Foghorn Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Conference

Nov 19, 2024, 7:00 AM EST - 1 year ago

Foghorn Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Nov 4, 2024, 4:05 PM EST - 1 year ago

Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update

Nov 4, 2024, 9:30 AM EST - 1 year ago

Foghorn Therapeutics Quarterly report: Q3 2024

Nov 4, 2024, 9:30 AM EST - 1 year ago

Foghorn Therapeutics Earnings release: Q3 2024

Oct 10, 2024, 7:00 AM EDT - 2 years ago

Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors

Oct 1, 2024, 7:00 AM EDT - 2 years ago

Foghorn Therapeutics to Participate in the BMO Oncology Summit

Sep 6, 2024, 8:30 AM EDT - 2 years ago

Foghorn Therapeutics Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Sep 3, 2024, 7:00 AM EDT - 2 years ago

Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business Officer

Aug 28, 2024, 7:00 AM EDT - 2 years ago

Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in September

Aug 8, 2024, 9:30 AM EDT - 2 years ago

Foghorn Therapeutics Quarterly report: Q2 2024

Aug 8, 2024, 9:30 AM EDT - 2 years ago

Foghorn Therapeutics Earnings release: Q2 2024

Aug 8, 2024, 7:00 AM EDT - 2 years ago

Foghorn Therapeutics Provides Second Quarter 2024 Financial and Corporate Update

May 28, 2024, 7:00 AM EDT - 2 years ago

Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June

May 22, 2024, 6:21 PM EDT - 2 years ago

Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline

May 20, 2024, 7:58 AM EDT - 2 years ago

Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants

May 6, 2024, 7:00 AM EDT - 2 years ago

Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update

May 6, 2024, 7:00 AM EDT - 2 years ago

Foghorn Therapeutics Quarterly report: Q1 2024

May 6, 2024, 7:00 AM EDT - 2 years ago

Foghorn Therapeutics Earnings release: Q1 2024

May 3, 2024, 8:00 AM EDT - 2 years ago

Foghorn Therapeutics Proxy statement: Proxy Filing

May 3, 2024, 8:00 AM EDT - 2 years ago

Foghorn Therapeutics Proxy statement: Proxy Filing

Apr 16, 2024, 7:00 AM EDT - 2 years ago

Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer

Apr 9, 2024, 5:00 PM EDT - 2 years ago

Foghorn Therapeutics Transcript: Status Update

Apr 9, 2024, 5:00 PM EDT - 2 years ago

Foghorn Therapeutics Press release: Status Update

Apr 9, 2024, 5:00 PM EDT - 2 years ago

Foghorn Therapeutics Slides: Status Update

Apr 9, 2024, 4:30 PM EDT - 2 years ago

Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs

Apr 5, 2024, 7:00 AM EDT - 2 years ago

Foghorn Therapeutics to Participate in Needham's 23rd Annual Virtual Healthcare Conference

Mar 26, 2024, 7:00 AM EDT - 2 years ago

Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting

Mar 7, 2024, 7:00 AM EST - 2 years ago

Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook

Mar 7, 2024, 7:00 AM EST - 2 years ago

Foghorn Therapeutics Earnings release: Q4 2023

Mar 7, 2024, 7:00 AM EST - 2 years ago

Foghorn Therapeutics Annual report: Q4 2023

Mar 5, 2024, 4:48 PM EST - 2 years ago

Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909

Feb 28, 2024, 7:00 AM EST - 2 years ago

Foghorn Therapeutics to Participate in Cowen's 44th Annual Health Care Conference

Dec 1, 2023, 7:00 AM EST - 2 years ago

Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM Inhibitor, in Patients with Advanced Hematologic Malignancies, to be Presented at American Society of Hematology Annual Meeting

Nov 2, 2023, 8:00 AM EDT - 3 years ago

Foghorn Therapeutics Quarterly report: Q3 2023

Nov 2, 2023, 8:00 AM EDT - 3 years ago

Foghorn Therapeutics Earnings release: Q3 2023

Nov 2, 2023, 7:00 AM EDT - 3 years ago

Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update

Oct 13, 2023, 8:00 AM EDT - 3 years ago

Foghorn Therapeutics Announces Clinical Data From Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma to Be Presented at ESMO Congress

Oct 4, 2023, 8:00 AM EDT - 3 years ago

Foghorn Therapeutics to Present Clinical and Pre-Clinical Data from Multiple Programs Across Its Diverse Pipeline at AACR-NCI-EORTC International Conference

AnomalyDetective Aug. 15 at 4:45 PM

0 · Reply

Zephix Aug. 13 at 11:08 PM

$FHTX Hog2

0 · Reply

AnomalyDetective Aug. 13 at 12:56 PM

0 · Reply

vu_jade Aug. 10 at 3:59 PM

$FHTX long term reversal going on

0 · Reply

AnomalyDetective Aug. 10 at 3:26 PM

0 · Reply

cea Aug. 7 at 10:11 PM

$FHTX $GSK $LLY $SLS $VKTX Has nothing to do with any of the other tickers. Stop spamming @Stocktwits reporting. BLOCKED!

0 · Reply

wyoming2020 Aug. 7 at 8:53 PM

$FHTX interesting move today $LLY Partnered lead for cancer

0 · Reply

wyoming2020 Aug. 7 at 8:50 PM

0 · Reply

RandomInvestor777 Jul. 14 at 4:41 PM

$FHTX why is this so dead volume wise

0 · Reply

justiceforb_85 Jul. 13 at 12:25 AM

1 · Reply

Innerchild Jul. 8 at 12:07 PM

$OMEX Shorters running out of Ammo, mega short squeeze soon just like $VRXA $SKIN $FHTX

0 · Reply

RakeTheProfit Jul. 7 at 8:07 PM

$FHTX a little quite for a 🔥 day. Love this one and been in for a bit. Timing has come.

1 · Reply

focafoca99 Jun. 24 at 8:14 PM

$FHTX ratified its 2026 annual meeting, electing three directors and approving Deloitte & Touche as auditor.

0 · Reply

NetworkNewsWire Jun. 22 at 3:48 PM

Next-Generation DNA Repair Therapies Open New Frontiers in Oncology ONCO.AQL $ONNVF $AZN $APRE $BOLD $FHTX https://ibn.fm/zrVjp

0 · Reply

a36er Jun. 11 at 7:08 PM

$FHTX Volume's picking up.

0 · Reply

LabPsycho Jun. 4 at 10:03 PM

$FHTX @theBigDollarski Exactly. And of course that is the image many think of when they see the name Foghorn. IMO, its right down there with "Gossamer ' biotech - just what I want to envision when thinking of biotech - a dusty ole spider web - LoL

1 · Reply

theBigDollarski Jun. 4 at 7:36 PM

$FHTX sad excuse for a company name......

0 · Reply

LabPsycho May. 25 at 1:57 PM

$FHTX @NotBornYesterday Good post. The concern I have is so many PROTAC companies and universities working on this stuff...what is unique about FHTX assets. Yeah, the preclinical looks interesting but need something in phase 2 for solid tumors to compete I think. Your thoughts?

2 · Reply

NotBornYesterday May. 15 at 11:10 AM

$FHTX In last 10 days, Fido and Deerfield have upped their stakes to 11.60% and 8.65%, respectively. Anybody care to guess timeframe on '909 decision? Looks like cash at end of 2Q could be ~$2.30/sh. At what share price is a '909 no-go decision already baked in? What curve balls could we get over remainder of 2026? If '909 no-go, can we still get positive surprise on LLY funding for other partnership programs? Bueller? Bueller? Anybody paying attention to this stock?

0 · Reply

Orlandotrader May. 14 at 7:57 PM

$FHTX Fart Horn. See you at 3.40 for some Snitzell.

0 · Reply

Orlandotrader May. 8 at 7:49 PM

$FHTX New position Today. A bit early but let’s Rock.

0 · Reply

BillionerOfKing May. 5 at 12:40 PM

$FHTX Current Stock Price: $4.68 Contracts to trade: $5.0 FHTX May 15 2026 Call Entry: $0.63 Exit: $1.02 ROI: 61% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Market Cap	400.26M
Revenue (ttm)	30.91M
Net Income (ttm)	-74.28M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-240.31%
Debt to Equity Ratio	0.00

Volume	153,900
Avg Vol	287,762
Day's Range	N/A - N/A
Shares Out	59.39M
Stochastic %K	92%
Beta	2.89
Analysts	Strong Sell
Price Target	$11.44